CHILD SYRUP HAVING NEUROLOGICAL ACTIVITY: INVESTIGATION OF STABILITY AND PHARMACOLOGICAL ACTIVITY

Download full text PDF
DOI: https://doi.org/None
Issue: 
7
Year: 
2015

T.D. Sineva, PhD; G.M. Alekseeva, PhD; T.S. Potekhina, PhD; N.Yu. Frolova, PhD Saint Petersburg State Chemopharmaceutical Academy, 14, Prof. Popov St., Saint Petersburg 197376

A technology of syrup having neurological activity was developed for young children. The syrup consisted of thiamine bromide, pyridoxine hydrochloride, cyanocobalamin, and sorbitol syrup as a dispersion medium. The syrup did not contain excipients that were unwanted for young children (stabilizers, dyes, aromatics), as well as ethanol and saccharose. Procedures were developed for the qualitative and qualitative analysis of all syrup ingredients. According to organoleptic indicators, the qualitative and quantitative content of all ingredients, microbiological purity, and technological parameters, the syrup was ascertained to be stable within 30 months (follow-up time). Animal experiments revealed that the syrup had anxiolytic activity.
Keywords: 
syrup
young children
thiamine bromide
pyridoxine hydrochloride
cyanocobalamin
sorbitol
stability
microbiological purity
neurological activity
References: 
  1. The Rules Governing Medicinal Products in the European Union. The Notice to Applicants. Volume 2C. Regulatory Guidelines. Guidelineon the Categorisation of Extension Applications (EA) versus Variations Applications (V). European Comission. Brussels, F2/AW D(2002), Final. Revision 3.
  2. EMEA/SHMR/167068/2004. ICH. Part I. ICHTopicQ 8(R2). Step 5: Notefor Guidanceon Pharmaceutical Development, 2009.
  3. Robertson T., Hendey G., Stroh G., Shalit M. Intranasal Naloxone is a Viable Alternative to Intravenous Naloxone for Prehospital Narcotic Overdose. Prehospital Emergency Care., 2009; 13. (4): 512–515.
  4. Gosudarstvennyy reestr lekarstvennyh sredstv Rossii [E`lektronnyy resurs]. Rezhim dostupa: http://grls.rosminzdrav.ru/ [State Register of medicinal products in Russia [electronic resource]. Access: http://grls.rosminzdrav.ru/ (in Russian)].
  5. European Pharmacopoeia. 8th Ed. European Directorate for the Quality of Medicines (EDQM). Council of Europe, 67075 Strasbourg Cedex, France 2013; 3655.
  6. Rowe R.C., Sheskey P.J., Owen S.C. (Eds.). Pharmaceutical Excipients. Pharmaceutical Press, London; Electronic version. 2006.
  7. Lugano A.S. Etude du transport de principles actifsincorporesdans des emulsions liquides de type huiledans eau: These doct. pharm. sci. – 1793. – Zurich, 1977: 117.
  8. Timchenko O.V., Bezuglaya E.P., Orlova I.N., Bariev E`.A. Farmakokineticheskoe obosnovanie koncentracii i dozy naloksona gidrohlorida pri farmacevticheskoy razrabotke preparata «Nalokson sprey nazal`nyy». Farmakom, 2013; 2: 30–37 [Timchenko O.V., Bezuglaya E.P., Orlova I.N., Bariev E.A. Pharmacokinetic study of concentration and dose of naloxone hydrochloride during pharmaceutical development of medicinal product «Naloxon enzal spray». Farmacom, 2013; 2: 30–37 (in Russian)].
  9. Boddupalli B.M., Zulkar N.K. Mohammed, Ravinder N.A., Banji D. Mucoadhesive drug delivery system: an overview. J. of Advanced Pharm. Technology&Research., 2010; 1. (4): 381–387.
  10. EMEA/CHMP/QWP/49313/2006 corr. Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products. London, 21 June 2006.